For the year ending 2025-12-31, CUE had $4,679K increase in cash & cash equivalents over the period. -$21,864K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -26,602 |
| Depreciation and amortization | 958 |
| Stock-based compensation | 4,744 |
| Decrease in the carrying amount of right-of-use assets | 2,522 |
| Amortization of premium/discount on purchased securities | -212 |
| Loss (gain) on fixed asset disposal | -31 |
| Amortization of debt issuance costs | 37 |
| Accretion of final payment of term loan | 130 |
| Accounts receivable | 4,601 |
| Prepaid expenses and other current assets | 1,115 |
| Deposits | 1,125 |
| Foreign withholding tax receivable | 1,899 |
| Accounts payable | 1,125 |
| Accrued expenses | -1,297 |
| Other payable | 689 |
| Research and development contract liability, current portion | 5,250 |
| Operating lease liability | -2,572 |
| Net cash used in operating activities | -21,687 |
| Purchases of property and equipment | 177 |
| Cash received from the sale of property and equipment | 40 |
| Purchases of marketable securities | 16,288 |
| Redemption of marketable securities | -16,500 |
| Net cash provided by investing activities | 75 |
| Proceeds from atm offering, net of sales agent commission and fees | 2,502 |
| Proceeds from issuance of common stock, warrants and pre-funded warrants, net of transaction costs | 28,289 |
| Repayment of term loans | -4,500 |
| Issuance of common stock upon exercise of warrants and pre-funded warrants, net | 0 |
| Net cash provided by financing activities | 26,291 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 4,679 |
| Cash, cash equivalents, and restricted cash at beginning of year | 22,611 |
| Cash, cash equivalents, and restricted cash at end of year | 27,290 |
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)